The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Subscribe To Our Newsletter & Stay Updated
